 Wave Life Sciences Ltds NASDAQ: WVE FOCUS-C9 study of WVE-004 shows reductions of polyGP dipeptide repeat proteins in cerebrospinal fluid CSF with low, single doses of WVE-004. The Phase 1b2a trial is assessing WVE-004 in C9orf72-associated amyotrophic lateral. 